Can you build immunity to allergy medication? It is a question many long-term allergy sufferers ask when their tablets or nasal sprays seem less effective than they once were. This article explores how antihistamines and intranasal corticosteroids work, what the evidence says about pharmacological tolerance, and why perceived reduced effectiveness is often explained by other factors. We also cover when to seek advice from a pharmacist or GP, and what alternatives — including allergen immunotherapy available on the NHS — may offer longer-lasting relief for conditions such as allergic rhinitis, urticaria, and allergic conjunctivitis.

How Allergy Medications Work in the Body

Allergy medications work by targeting specific steps in the body's immune response to airborne or contact allergens such as pollen, dust mites, and pet dander. This article focuses on the management of allergic rhinitis, allergic conjunctivitis, and urticaria — conditions for which antihistamines and intranasal corticosteroids are appropriate treatments. Food allergy is a distinct condition managed differently, primarily through allergen avoidance and, where indicated, an emergency action plan including adrenaline auto-injectors; it is not addressed here.

When the immune system encounters an allergen, it triggers the release of histamine and other chemical mediators from mast cells and basophils. These chemicals are responsible for the familiar symptoms of allergic rhinitis, urticaria, and conjunctivitis — including sneezing, itching, watery eyes, and nasal congestion.

Antihistamines, the most commonly used allergy medications, work by blocking H1 histamine receptors, thereby preventing histamine from binding and triggering symptoms. First-generation antihistamines (such as chlorphenamine) cross the blood-brain barrier and can cause sedation — patients taking them should not drive or operate machinery. Second-generation antihistamines (such as cetirizine, loratadine, and fexofenadine) are largely non-sedating and are preferred for regular use in line with NICE CKS guidance on allergic rhinitis.

Other allergy medications include:

• Intranasal corticosteroids (e.g., fluticasone, mometasone) — which reduce local airway inflammation and are considered first-line treatment for moderate-to-severe allergic rhinitis by NICE

• Intranasal antihistamines (e.g., azelastine) — which act locally and rapidly; a combination intranasal corticosteroid/antihistamine spray (fluticasone/azelastine) is also available for more troublesome symptoms

• Leukotriene receptor antagonists (e.g., montelukast) — which block inflammatory mediators beyond histamine; montelukast is not a first-line treatment for allergic rhinitis and carries an MHRA Drug Safety Update warning regarding neuropsychiatric reactions (including sleep disturbances, anxiety, and mood changes); it should only be used under clinician supervision, particularly in patients with concomitant asthma

• Mast cell stabilisers (e.g., sodium cromoglicate) — which prevent the release of histamine

• Decongestants (e.g., xylometazoline nasal spray, pseudoephedrine) — which relieve nasal congestion but should only be used short-term (no more than 7 days for topical preparations) due to the risk of rebound congestion (rhinitis medicamentosa); they should be avoided in certain cardiovascular conditions and during pregnancy unless specifically advised by a clinician

Each class of medication acts at a different point in the allergic cascade, which is why combination therapy is sometimes recommended for more severe or persistent symptoms. Suspected side effects from any allergy medication can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

What Is Antihistamine Tolerance and Does It Occur?

The question of whether you can build immunity — or more accurately, tolerance — to allergy medication is a common concern among long-term users. Tolerance, in pharmacological terms, refers to a reduced response to a drug following repeated exposure, often requiring higher doses to achieve the same effect. This is well-documented with certain drug classes, such as opioids and benzodiazepines, but the picture with antihistamines is more nuanced.

With first-generation antihistamines, there is some clinical observation suggesting that tachyphylaxis (a rapid reduction in response) may develop with respect to sedative effects. The precise mechanism is not fully established, and patients should not increase their dose to compensate; doing so raises the risk of adverse effects without a clear evidence base for benefit.

Second-generation antihistamines, which are the standard recommendation for allergic rhinitis and urticaria in the UK, are generally considered to have a low risk of tolerance development. Clinical studies evaluating cetirizine and loratadine over extended treatment periods have not consistently demonstrated clinically meaningful tachyphylaxis at licensed doses, and the EAACI/ARIA allergic rhinitis guidelines do not identify tolerance as a primary concern with these agents used as directed.

It is important not to exceed the licensed dose of antihistamines for allergic rhinitis. Up-dosing (for example, to up to four times the standard dose) is a strategy used specifically in chronic spontaneous urticaria, but only under specialist supervision in line with BSACI and EAACI guidance — it is not appropriate for self-management of hay fever or rhinitis.

What may feel like reduced effectiveness is often attributable to other factors — such as increased allergen exposure, disease progression, or suboptimal administration — rather than true pharmacological tolerance. These are explored in the following section.

Signs Your Allergy Medication May Be Less Effective

If you have been taking the same allergy medication for a prolonged period and feel it is no longer controlling your symptoms adequately, it is worth considering several possible explanations before concluding that you have developed tolerance to the drug.

Common signs that your medication may be less effective include:

• Symptoms returning or worsening despite consistent use

• Needing to take doses more frequently than prescribed or recommended

• Experiencing breakthrough symptoms during peak allergen seasons

• Noticing that symptoms which were previously well-controlled are now interfering with daily life or sleep

However, these signs do not necessarily indicate pharmacological tolerance. Allergy symptoms naturally fluctuate depending on pollen counts, indoor allergen levels, and seasonal variation. A particularly high pollen season may simply overwhelm the protective effect of a standard antihistamine dose. Similarly, if you have developed new sensitivities to additional allergens, your existing medication may not cover the full spectrum of triggers.

It is also worth reviewing whether the medication is being taken correctly:

• Intranasal corticosteroids require consistent daily use to achieve their full anti-inflammatory effect. Symptom relief may begin within a few hours of the first dose, but maximal benefit typically takes several days to two weeks of regular use. Using them only on symptomatic days significantly reduces their efficacy. Correct spray technique — directing the nozzle towards the outer wall of the nostril rather than the nasal septum — also affects how well they work.

• Antihistamines are more effective when taken prophylactically (before allergen exposure) rather than reactively once symptoms have already developed.

Allergen avoidance measures can also make a meaningful difference to perceived medication efficacy. Practical steps include checking daily pollen forecasts, keeping windows closed during high pollen periods, showering after outdoor exposure, using saline nasal rinses, and implementing dust-mite reduction measures (such as allergen-proof mattress covers and regular hot washing of bedding) where relevant.

Before assuming tolerance has developed, a structured review of your medication regimen with a pharmacist or GP is advisable.

What the Evidence Says About Long-Term Use

The scientific literature on long-term antihistamine use provides some reassurance for patients concerned about building immunity to their allergy medication. Several clinical trials have examined the sustained efficacy of second-generation antihistamines over periods ranging from weeks to months, with broadly positive findings.

Studies evaluating cetirizine and loratadine over 12-week and longer treatment periods have not found statistically significant reductions in symptom control scores compared to baseline, suggesting that clinically meaningful tolerance does not commonly develop with these agents at licensed doses. The EAACI/ARIA allergic rhinitis guidelines similarly do not identify tolerance as a primary concern with second-generation antihistamines used as directed.

That said, individual variation exists. Some patients do report a subjective reduction in effectiveness over time, and whilst this may not always reflect true pharmacological tolerance, it is a clinically relevant experience that warrants attention. In such cases, switching between second-generation antihistamines — for example, from cetirizine to fexofenadine — is a pragmatic strategy sometimes employed in clinical practice, as referenced in NICE CKS and BSACI guidance, though robust head-to-head evidence specifically supporting this approach remains limited.

For intranasal corticosteroids, long-term use is well-supported by evidence and these agents are considered first-line treatment for moderate-to-severe allergic rhinitis by NICE. Modern intranasal corticosteroids such as fluticasone furoate and mometasone furoate have very low systemic bioavailability, and their safety and tolerability profile with long-term use is well-characterised in their MHRA-approved Summary of Product Characteristics (SmPC). There is no established mechanism by which tolerance to their anti-inflammatory effects develops with regular use, making them a reliable option for ongoing symptom management.

When to Speak to a GP or Pharmacist

Whilst many allergy symptoms can be managed effectively with over-the-counter medications, there are circumstances in which it is important to seek professional advice. A pharmacist is an excellent first point of contact for reviewing your current medication regimen, advising on correct administration, and suggesting alternatives if your current treatment appears insufficient.

Seek emergency help immediately (call 999) if you experience:

• Difficulty breathing, wheezing, or a tight chest

• Swelling of the lips, tongue, throat, or face

• Dizziness, collapse, or loss of consciousness

• A sudden severe allergic reaction (anaphylaxis) or a severe asthma attack

These are medical emergencies and require immediate treatment.

You should speak to a GP if:

• Your allergy symptoms are significantly affecting your quality of life, sleep, or ability to work or study

• Over-the-counter antihistamines and nasal sprays are no longer providing adequate relief

• You are experiencing symptoms year-round rather than seasonally, which may suggest perennial allergic rhinitis or a non-allergic cause

• You develop new or worsening symptoms such as facial pain or pressure, persistent loss of smell, or persistent nasal blockage — particularly if one-sided, or accompanied by bleeding or systemic symptoms — as these may indicate sinusitis, nasal polyps, or, rarely, other conditions requiring prompt assessment

• You are considering long-term or high-dose use of any allergy medication

• There is any suspicion of a more serious allergic condition, such as asthma

A GP can arrange specific IgE blood tests to help identify your triggers more precisely, which in turn allows for more targeted treatment. Skin prick testing is typically performed in specialist allergy clinic settings rather than in primary care. GPs can also prescribe higher-strength intranasal corticosteroids, combination therapies, or refer you to a specialist allergy clinic or ENT service if appropriate.

Note that first-generation antihistamines (such as chlorphenamine) cause sedation and impair the ability to drive or operate machinery — patients should be advised of this before use.

Early review is particularly important in children, as poorly controlled allergic rhinitis can impact sleep, school performance, and asthma control.

Alternatives and Immunotherapy Options Available on the NHS

If standard allergy medications are no longer providing sufficient relief, or if you are seeking a longer-term solution rather than ongoing symptom suppression, allergen immunotherapy represents a clinically validated alternative. Unlike antihistamines, which manage symptoms, immunotherapy aims to modify the underlying immune response to specific allergens — offering the potential for sustained benefit even after treatment ends.

Allergen immunotherapy is available in two main forms:

• Subcutaneous immunotherapy (SCIT) — a course of injections administered in a clinic setting, gradually increasing the dose of allergen to build tolerance

• Sublingual immunotherapy (SLIT) — allergen delivered as dissolvable tablets or drops placed under the tongue

Immunotherapy is initiated and supervised by specialist allergy services, not in primary care. This is because there is a risk of systemic allergic reactions, including anaphylaxis, particularly with SCIT; patients must be monitored after each dose and have access to emergency treatment. SLIT products are generally considered to carry a lower risk of systemic reactions but still require specialist assessment and supervised initiation.

Several SLIT tablet products are licensed in the UK for use in specialist settings:

• Grass pollen allergic rhinitis: products such as Grazax® (ALK) and Oralair® are licensed for grass pollen allergy

• Birch pollen allergic rhinitis: Itulazax® is licensed for birch pollen allergy (with cross-reactivity to related tree pollens)

• House dust mite allergic rhinitis or mild-to-moderate allergic asthma: Acarizax® is licensed for eligible patients

Age indications, eligibility criteria, and contraindications vary by product; full details are available in each product's MHRA-approved Summary of Product Characteristics (SmPC) and EMA European Public Assessment Report (EPAR). Access to immunotherapy on the NHS is subject to local commissioning decisions and specialist assessment in line with BSACI, ARIA, and NICE CKS guidance.

Treatment courses generally last three years, and clinical evidence supports meaningful reductions in symptom scores and medication use, with benefits persisting for several years after treatment ends.

For patients who are not suitable for immunotherapy, reviewing the full range of pharmacological options — including combination intranasal corticosteroid/antihistamine sprays, leukotriene receptor antagonists (under specialist supervision), or referral to ENT for structural causes — ensures that all avenues are explored before concluding that medication has simply stopped working.

Frequently Asked Questions